Clinical Trial Update: Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia [Phase 2]

View source ↗

Summary

This update summarizes the completion of a Phase 2 safety and cognitive function study of EVP-6124 in patients with schizophrenia. The trial was sponsored by FO…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• EVP-6124

Snippet

Sponsor: FORUM Pharmaceuticals Inc | Conditions: Schizophrenia, Central Nervous System Diseases | Phase 2 | Status: COMPLETED